- 5th - 6th April 2027
- London, United Kingdom
Precision Medicine Global Congress 2027 Europe
Advancing Precision Medicine Through Innovation, Collaboration, and Sustainable Access
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
precision for medicine
Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to a subgroup of patients, instead of a one‐drug‐fits‐all model
Dear Colleagues,
FACILITATE LIVE is delighted to bring together the global precision medicine community for the Precision Medicine Global Congress 2027 Europe, a leading platform dedicated to advancing the science, clinical application and commercial development of personalised healthcare.
Precision medicine is entering a transformative era, driven by breakthroughs in multi omics, spatial biology, artificial intelligence, genomic medicine, programmable therapeutics and advanced cell and gene therapies. These developments are fundamentally changing how diseases are understood, diagnosed, prevented and treated. From AI-driven drug discovery and precision diagnostics to CRISPR-based gene editing and next-generation RNA therapeutics, scientific innovation is creating unprecedented opportunities to deliver more targeted, effective and individualised treatments.
However, translating these breakthroughs into routine clinical practice requires more than scientific progress. Healthcare systems must address the growing complexity of clinical validation, regulatory approval, data interoperability, manufacturing scalability, reimbursement and equitable access. As precision medicine moves from research and development towards broader clinical implementation, collaboration across pharmaceutical companies, biotechnology innovators, diagnostic developers,
healthcare providers, regulators, payers and patient organisations will be essential.
The Precision Medicine Global Congress 2027 Europe will bring together international experts and industry decision-makers to explore these challenges and opportunities. Through keynote presentations, plenary sessions, sponsored spotlights and strategic panel discussions, the congress will examine the
technologies, partnerships and implementation strategies shaping the next generation of precision healthcare.
Across both days, three interconnected priorities will shape the discussions. First, scientific and technological convergence will accelerate the transition towards more predictive, preventive and personalised healthcare. Second, successful clinical translation will depend on robust evidence generation, regulatory clarity, interoperable data infrastructure and sustainable commercial models. Third, equitable access will require coordinated action across industry, healthcare systems, governments, regulators,
payers and patient communities.
Ultimately, the future of precision medicine will be determined not only by the ability to develop ground breaking technologies, but by the collective capacity to translate them into clinically meaningful, economically sustainable and globally accessible healthcare solutions.
The defining challenge ahead is clear: transform scientific breakthroughs into real-world patient impact and make the promise of precision medicine accessible to all.
We look forward to welcoming you to the congress!
Sincerely yours,
Jocelyn Raguindin,
Conference Director,
FACILITATE LIVE
KEY INSIGHTS AND LESSONS:
- Advancing precision medicine towards predictive, preventive and personalised healthcare through integrated multi omics and genomic intelligence.
- Harnessing single cell sequencing, spatial transcriptomics and multi-omics to uncover disease mechanisms and novel therapeutic targets.
- Leveraging generative AI, foundation models and computational biology to accelerate drug discovery and precision therapeutic development.
- Advancing liquid biopsy, circulating tumour DNA (ctDNA) and minimal residual disease (MRD) technologies for early detection and disease monitoring.
- Integrating clinical genomics and pharmacogenomics into routine healthcare to optimise treatment selection and improve patient outcomes.
- Developing biomarker-driven precision oncology through molecular profiling, companion diagnostics and personalised treatment strategies.
- Applying multimodal AI, digital twins and predictive analytics to transform clinical decision-making and individual patient management.
- Redesigning clinical trials through adaptive, basket, umbrella and platform designs, supported by AI driven recruitment and real-world evidence.
- Expanding population-scale genomics, inclusive reference genomes and global biobanks to advance precision healthcare and genomic diversity.
- Establishing federated learning, privacy-preserving computing and interoperable data ecosystems for secure genomic research and responsible AI adoption.
- Advancing programmable medicine through CRISPR, base editing, prime editing and next generation in-vivo gene-editing technologies.
- Accelerating next generation cell therapies, including CAR-T, allogeneic and engineered immune-cell platforms for cancer and autoimmune diseases.
- Expanding RNA therapeutics, including mRNA, siRNA, antisense oligonucleotides and circular RNA, through innovative delivery technologies. Scaling advanced therapy manufacturing while navigating regulatory innovation, GMP requirements, sustainable reimbursement and commercialisation challenges.
- Closing the global precision medicine gap through international collaboration, inclusive clinical research, affordable diagnostics and equitable access to advanced therapies
Who should attend:
This forum is designed for senior leaders and decision makers across the personalised medicine ecosystem, including:
Pharmaceutical & Biotechnology Executives
- CEOs, CSOs, CMOs, Heads of R&D
- Precision Medicine Leaders
- Gene & Cell Therapy Directors
- Regulatory Affairs, Market Access
- Advanced Therapy Manufacturing Executives
Healthcare System & Clinical Leaders
- Chief Medical and Digital Officers
- Genomic Medicine Directors
- Oncology & Rare Disease Program Leads
- Clinical Trial Directors
- Molecular Pathology Heads
Government & Regulatory Authorities
- Regulatory Agency Representatives
- HTA Leaders
- National Genomics Program Directors
- Public Health Policymakers
- Health Innovation Advisors
Payers & Health Economics Experts
- Reimbursement Authorities, HEOR Leaders
- Insurance Executives
- Value-Based Contracting Specialists
- Budget Impact Strategists
Technology & Data Infrastructure Leaders
- Chief Technology Officers
- AI & Health Data Platform Executives Interoperability Strategists
- Cybersecurity Leaders
- Digital Health Innovators
Diagnostics & Manufacturing Specialists
- Companion Diagnostics Executives
- Laboratory Network Directors
- CDMO Leaders
- GMP Operations Heads
- Bioprocess Engineering Experts
Patient Advocacy & Non-Profit Leaders
- Patient Organization Executives
- Health Equity Advocates
- Access Policy Leaders
Academic & Research Institutions
- Translational Scientists, Genomics Researchers
- Clinical Investigators
- Bioinformatics Leaders
- Health Policy Experts
speakers
0
days
0
Presentations
0
Attendees
0
Key Industry Expert Speakers
Meet Our Professionals
Soming Soon
Senior Representative
Soming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Coming Soon
Senior Representative
Schedule
Our Conference Production Team are now at the final stages of the overall complete program agenda - which will be available below shortly.
Translating scientific breakthroughs into scalable clinical systems
09:00 - OPENING KEYNOTE PANEL: Scaling Personalised Medicine: From Innovation to System-Level Impact
- Moving beyond pilot programs to national-scale implementation
- Aligning regulatory pathways with innovation speed
- Evidence generation: what payers and governments require
- Co-development models (drug + diagnostic + digital companion)
- Embedding patient voice early in therapeutic design
- Analyzing current adoption rates and regional developments across international markets.
- Examining the evolving frameworks designed to bring personalized therapies to market more efficiently.
- Identifying the systemic and technological hurdles that currently limit widespread scalability.
- Developing actionable strategies to integrate these advancements into standard healthcare delivery.
- Explore the integration of genomics, transcriptomics, proteomics, and metabolomics
- Focus on the role of systems biology in disease stratification
- Address the clinical validation of multi-omic signatures
- The ongoing challenges regarding data interoperability
- Strategies for translating these complex datasets into physician-ready insights that can be applied in a
clinical setting.
- Transitioning from research sequencing to clinical-grade pipelines
- Harmonizing variant interpretation across institutions
- Integrating genomic data into hospital EHR systems
- Accreditation, quality assurance, and compliance frameworks
- Workforce and bioinformatics capacity building
- Embedding PGx into electronic health record-based prescribing systems to provide real-time decision support.
- Utilizing genotype-guided therapy to significantly reduce adverse drug reactions.
- Establishing robust cost-effectiveness evidence to secure support from payers.
- Developing national implementation frameworks to standardize practices.
- Identifying and overcoming barriers to clinician adoption through education and streamlined workflows.
- Strategies for aligning drug and diagnostic timelines.
- Navigating cross-agency requirements and ensuring compliance.
- Standards for establishing clinical validity and utility.
- Synchronizing strategies between pharmaceutical and diagnostic partners to ensure market access and sustainable reimbursement.
The Data-Driven Infrastructure of Precision Medicine
- Examining computational models for treatment optimization
- Use of predictive modeling for disease progression.
- The integration of wearable and remote monitoring data to enhance model accuracy.
- Ethical implications of predictive health forecasting
- Practical challenges of clinical adoption and reimbursement.
- Multi-modal AI models integrating imaging, omics, and EHR data
- Validation frameworks for AI-derived biomarkers
- Bias detection and mitigation in training datasets
- Regulatory approval pathways for AI-driven diagnostics
- Real-world performance monitoring
- Leveraging longitudinal EHR and claims data
- Synthetic control arms in rare disease trials
- Data standardization and quality frameworks
- Global regulatory acceptance trends
- RWE in post-market surveillance
- Focus on establishing cross-border genomic data sharing frameworks
- Implementation of federated AI models that function without the need for centralizing sensitive data.
- Addressing critical cyber security threats facing genomic infrastructure and the modernization of patient consent processes.
- Effective strategies that balances technological innovation with the maintenance of public trust.
- Implementation of basket, umbrella, and platform trial designs
- Biomarker-driven patient stratification to ensure more targeted treatment.
- Transition toward decentralized and hybrid trial models to increase patient accessibility
- AI-assisted patient recruitment and advocating for the global harmonization of trial regulations.
- Who owns genomic and real-world data?
- Public-private data partnerships: risks and opportunities
- Balancing innovation with privacy protection
- Data standardization and interoperability challenges
- Building patient trust in AI-driven healthcare
Advanced Therapies & Convergent Innovation
- Exploring the clinical readiness of advanced therapies for mainstream adoption and the factors defining clinical maturity
- Evaluating whether regulatory frameworks can keep pace with programmable medicine.
- Determining if healthcare infrastructure is sufficiently prepared.
- Discussing how to balance speed with safety.
- Defining what responsible innovation looks like in 2026 and beyond
09:45 - PLENARY KEYNOTE: Gene Editing in Clinical Practice: Translating CRISPR into Standard of Care
- Analysis of clinical data currently emerging from CRISPR, base editing, and prime editing trials
- Practical considerations regarding in vivo versus ex vivo delivery methods
- Essential frameworks and registries required for long-term safety monitoring.
- Regulatory pathways for first-in-class editing therapies
- How health systems can best prepare for the implementation of curative genomic interventions.
- Expansion of CAR-T into autoimmune and rare conditions
- Development of allogeneic and off-the-shelf platforms to improve scalability.
- Operational challenges of managing toxicity and long-term follow-up requirements
- Strategies for manufacturing and turnaround optimization
- Significant reimbursement implications associated with these curative cell therapies.
- Expanding the application of mRNA technologies into broader therapeutic areas.
- Exploring innovative technologies for precise genetic adjustments and modulation.
- Improving tissue targeting and the efficiency of delivery mechanisms.
- Navigating the evolving regulatory landscape for novel RNA modalities.
- Refining models for expedited development to ensure effective global deployment.
- Combining genomics, imaging, wearables, and EHR data
- Development of more robust clinical decision support tools
- Application of digital twin modeling for treatment optimization
- Rigorous algorithm validation and transparency to support innovations
- Addressing the complexities of maintaining continuous learning systems within strictly regulated environments.
- Adaptive trial designs for gene and cell therapies
- Biomarker-driven patient stratification
- Real-world evidence integration into approval pathways
- Decentralized monitoring for complex therapies
- Global regulatory coordination for novel platforms
Access, Sustainability & System Readiness for Advanced Therapies
- Outcome-based reimbursement and annuity payment models.
- Long-term durability data and evidence requirements for curative treatments.
- Budget impact versus lifetime value calculations.
- Risk-sharing agreements between payers and manufacturers.
- National policy frameworks designed for high-cost therapies.
- Implementing advanced technologies within GMP environments to enhance efficiency.
- Strategies to lower the cost of goods for personalized treatments.
- Ensuring a stable supply of viral vectors and essential raw materials.
- Establishing localized facilities to improve global access to therapies.
- Standardizing compliance across international manufacturing sites.
- Establishing standards for specialized treatment center accreditation
- Developing comprehensive workforce training programs tailored for the delivery of gene and cell therapies.
- Prioritizing the implementation of registries for long-term patient monitoring to track longitudinal outcomes accurately
- Integrating genomic testing directly into hospital systems
- Improving cross-institutional care coordination will also be vital to ensuring seamless patient transitions and high-quality care
- Identifying critical barriers to equitable healthcare and identify actionable strategies for more inclusive innovation
- Addressing the significant gaps within genomic and clinical trial datasets to ensure therapies are effective for diverse populations.
- Developing robust technology transfer models specifically tailored for low- and middle-income countries.
- Facilitating public–private partnerships to ensure the equitable deployment of advanced treatments.
- Establishing ethical allocation frameworks for scarce therapies and exploring policy-driven incentives to foster inclusive innovation.
- Can healthcare systems absorb the cost of curative therapies at scale?
- Are we building sustainable manufacturing ecosystems?
- What is the ethical obligation of industry and government?
- Will advanced therapies widen global inequity?
- What structural reforms must happen in the next 5 years?
Newsletter Sign Up
No Spam – You will only receive relevant information on Personalized Medicine, and event updates
Testimonials
what people say
From a patient advocacy organization perspective, was a very informative meeting. Learned a lot from presentations and networking that will inform how we can add value to the advocacy-patient-drug developer dialogue.
Dr. Nadine Tutton
Scientific Director, Research, Association for Frontotemporal Degeneration
Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
SALVADOR BERRIOS
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
THOMAS MARTIN
Associate Vice President, VCGA - Quintiles
Previous events
Register to Attend now!
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.
Location
- London, UK
- info@paradigmglobalevents.com
- +44 (0) 207 193 3485